Gap junction beta‐4 accelerates cell cycle progression and metastasis through MET–AKT activation in pancreatic cancer
Cancer Science · 2024
DOI: 10.1111/cas.16101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Joji Muramatsu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: Cell Proliferation, Connexins, Pancreatic Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Despite continuing advances in the development of effective new therapies, including immunotherapies, the prognosis of pancreatic cancer remains extremely poor. Gap junction proteins have become attractive targets for potential cancer therapy. However, the role of gap junction beta‐4 (GJB4) protein remains unexplored in pancreatic cancer. Through bioinformatic analyses we discovered pancreatic cancer tissues showed higher levels of GJB4 transcripts compared to normal pancreatic tissues and this had a negative effect on overall survival in patients that had pancreatic cancer. The high expression of nuclear GJB4 was identified as a negative prognostic factor in such patients. Knockdown of GJB4 in cultured pancreatic cancer cells resulted in G 0 /G 1 arrest followed by decreased cell proliferation and suppression of metastatic potential. The overexpression of GJB4 accelerated cell proliferation, migration, and invasion in a SUIT‐2 cell line, whereas MET inhibitor canceled the acceleration. GJB4 suppression with siRNA significantly inhibited tumor growth in a mouse xenograft model. Mechanistically, suppression of GJB4 inhibited MET–AKT activities. Such data suggest that targeting the GJB4–MET axis could represent a promising new therapeutic strategy for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Cell Science, Research Institute for Frontiers Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
- Department of Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan.
ORCID-Profile: Joji Muramatsu
Zitieren
APA
Muramatsu, J., Arihara, Y., Yoshida, M., Kubo, T., Nakamura, H., Ishikawa, K., Fujita, H., Sugita, S., Konno, T., Kojima, T., Kawano, Y., Kobune, M., & Takada, K. (2024). Gap junction beta‐4 accelerates cell cycle progression and metastasis through MET–AKT activation in pancreatic cancer. Cancer Science. https://doi.org/10.1111/cas.16101
Vancouver
Muramatsu J, Arihara Y, Yoshida M, Kubo T, Nakamura H, Ishikawa K, et al. Gap junction beta‐4 accelerates cell cycle progression and metastasis through MET–AKT activation in pancreatic cancer. Cancer Science. 2024. doi:10.1111/cas.16101
BibTeX
@article{Muramatsu2024,
author = {Muramatsu, Joji and Arihara, Yohei and Yoshida, Makoto and Kubo, Tomohiro and Nakamura, Hajime and Ishikawa, Kazuma and Fujita, Hiromi and Sugita, Shintaro and Konno, Takumi and Kojima, Takashi and Kawano, Yutaka and Kobune, Masayoshi and Takada, Kohichi},
title = {Gap junction beta‐4 accelerates cell cycle progression and metastasis through MET–AKT activation in pancreatic cancer},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16101}
}
EUVIMED